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Abstract: Epstein–Barr virus (EBV) was first discovered in cells from a patient with Burkitt lymphoma
(BL), and is now known to be a contributory factor in 1–2% of all cancers, for which there are as
yet, no EBV-targeted therapies available. Like other herpesviruses, EBV adopts a persistent latent
infection in vivo and only rarely reactivates into replicative lytic cycle. Although latency is associated
with restricted patterns of gene expression, genes are never expressed in isolation; always in groups.
Here, we discuss (1) the ways in which the latent genes of EBV are known to modulate cell death,
(2) how these mechanisms relate to growth transformation and lymphomagenesis, and (3) how EBV
genes cooperate to coordinately regulate key cell death pathways in BL and lymphoblastoid cell lines
(LCLs). Since manipulation of the cell death machinery is critical in EBV pathogenesis, understanding
the mechanisms that underpin EBV regulation of apoptosis therefore provides opportunities for
novel therapeutic interventions.
Keywords: EBV; apoptosis; genetic cooperation; latency; virus cancers; p53; BCL-2 family;
growth transformation
1. Introduction
All viruses possess methods to negotiate and subvert the cell death pathways of their hosts, but for
viruses such as influenza that lead to acute infections, the battle for host cell survival is ultimately lost
when the host clears the virus. Persistent viruses however, such as those of the herpesvirus family
that are carried by the host for life, must avoid elimination by immune cells, whilst continuing to
disseminate within the host and avoid being lost through normal cell turnover. Human herpesvirus
4, also known as Epstein–Barr virus (EBV), is extremely efficient at establishing a persistent life-long
infection in human B cells. Most primary infections occur asymptomatically in early childhood
and by adulthood the majority (95% world-wide) of the adult population are infected with EBV [1].
Somewhat paradoxically, given the ubiquitous and asymptomatic nature of infection, EBV is the
archetypal human tumour virus. EBV was first associated with an unusual and aggressive form
of childhood lymphoma in 1964 [2,3], and is now known to contribute to over 200,000 new cancer
diagnoses each year [4]. These unusual characteristics are, in part, due to the many and various ways
EBV has evolved to exhibit exquisite control over cell death. Here, we review the mechanisms by
which EBV genes co-operate to regulate cell death and how this may contribute to lymphomagenesis
by focussing on evidence from the study of in vitro transformation of B cells and Burkitt lymphoma,
the cancer in which EBV was discovered.
The existence of EBV was first suspected by Denis Parsons Burkitt, a surgeon working in post-war
Uganda. In 1958, he published the first detailed clinical study of a strange lymphoma affecting the
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jaws and abdomens of children across sub-Saharan Africa [5]. He was struck by both the prevalence
and the poor prognosis of the disease: the tumours accounted for more cases of cancer in childhood
than all other malignancies combined and furthermore, were often rapidly fatal [6]. Burkitt lymphoma
(BL), as it came to be known, also had an unusual geographical distribution which overlapped
almost perfectly with that of arthropod borne infectious diseases such as Yellow Fever and Rift
Valley Fever [7–10]. A chance meeting with the then animal virologist, Anthony Epstein, led to the
search for a possible viral cause of BL and in 1964 the first micrographs showing the unmistakable
icosahedral structures of a previously undescribed herpesvirus were published [2]. It did however take
several more years until Epstein–Barr virus (named after Epstein and his PhD student, Yvonne Barr)
was convincingly shown to be an aetiological agent in BL and other cancers (reviewed in detail
elsewhere [11,12]).
2. ‘Transforming’ Cell Death: Latent Genes
The oncogenic potential of EBV was first demonstrated experimentally in 1967, when it
was observed that co-culturing lethally-irradiated, EBV-producing BL cells with primary human
lymphocytes led to the outgrowth of permanently proliferating lymphoblastoid cell lines (LCLs) [13,14].
This process of growth transformation, by which EBV is able to immortalise B lymphocytes that would
otherwise senesce and die in vitro, provided an important model for the study of EBV infection and
has therefore been extensively researched. Clearly, the activation of resting B cells into cell cycle is
imperative for growth transformation, but inhibition of cell death is equally essential. Although the
virus encodes around 100 open reading frames (ORFs), the vast majority of EBV genes have replicative,
immune suppressive or structural functions and as such are only expressed during the viral lytic
cycle [1]. EBV establishes a largely latent infection in infected cells (the virus is lytic in around 1% of
cells at any given time), where it is maintained as an episome by virtue of its ability to ‘piggy back’
onto the host replication machinery during mitosis [15,16]. During these latent infections, only a
small subset of EBV-encoded gene products is expressed [17,18]. In established LCLs (immortalised B
cells) EBV displays a Latency III pattern of infection. Latency III is the most extensive form of latent
infection, involving the expression of ten EBV-encoded proteins and a variety of non-coding RNAs.
These are the Epstein–Barr Nuclear Antigens (EBNA-1, EBNA-2, EBNAs-3A, -3B, -3C and EBNA-LP),
Latent Membrane Proteins (LMP1, LMP2A and LMP2B), and the viral BCL-2 homologue, BHRF1;
as well as two non-coding RNAs (EBER1 and EBER2), and two families of microRNAs encoded within
the BamHI A rightward transcripts (BARTs) and the BHRF1 locus (BHRF1 miRNAs), respectively
(Figure 1) [18–24]. These EBV latent gene products are expressed at different time points post-infection
of B cells, finally leading to growth transformation.
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Figure 1. Patterns of latent gene expression found in Epstein–Barr virus (EBV)-associated 
malignancies and growth transformed B cell lines. Schematic showing: the Latency III EBV gene 
expression programme, as found in B cells transformed in vitro into lymphoblastoid cell lines (LCLs); 
Latency I EBV gene expression as found in the majority (85%) of EBV-positive Burkitt lymphomas 
(BL); Wp-restricted latency (Wp Latency), as found in a minority (15%) of EBV-positive BLs (termed 
Wp-BL); and Latency II EBV gene expression, which is found in EBV-positive Hodgkin lymphoma 
(HL) as well as the EBV-associated epithelial malignancies, nasopharyngeal carcinoma (NPC) and 
gastric carcinoma (GC). Latent proteins (EBNA1, EBNA2, EBNA3A, EBNA3B, EBNA3C, EBNA-LP, 
BHRF1, LMP1 and LMP2A/B) are shown in blue. Non-coding RNAs (EBERs, miR-BHRF1s and miR-
BARTs) are shown in red, and selected latent promoters (Cp, Wp and Qp) are shown in green. 
Connecting lines denote splicing patterns, whilst blocks indicate exons. In Wp-BL, EBNA-LP is 
truncated due to a genomic deletion and is therefore denoted as t-EBNA-LP. 
2.1. Dynamics of Early Infection 
Upon infection of resting B cells, EBV gene expression, driven by host cell RNA polymerase II, 
begins almost immediately; the Wp promoter that drives early latent gene expression reaches 
maximal activity around 8–12 h post-infection (PI). These long and differentially spliced Wp-
transcripts preferentially encode EBNA-LP, EBNA-2 and BHRF1 [25,26]. The nuclear antigens 
(EBNAs-LP and -2) then transactivate the Cp and LMP promoters [27–29], leading to the expression 
of EBNA1, EBNA3A, -3B and -3C and LMP1, 2A and 2B, respectively, which reach peak expression 
at 2–3 days PI [25,30]. Importantly however, there is a delay between maximal expression of latent 
transcripts and the proteins they encode. The EBNA2, EBNA-LP and BHRF1 proteins reach levels 
comparable to those in established LCLs at around 72 h [25,31], whereas LMP1 protein is low or 
undetectable until 5 days PI. [19,32]. Expression of EBV non-coding RNAs is similarly delayed: they 
are not detected at appreciable levels until several days after infection (Figure 2). Many of these EBV 
genes are reported to have roles in cell proliferation and/or survival. 
Figure 1. Patterns of latent gene expression found in Epstein–Barr virus (EBV)-associated malignancies
and growth transformed B cell lines. Schematic showing: the Latency III EBV gene expression programme,
as found in B cells transformed in vitro into lymphoblastoid cell lines (LCLs); Latency I EBV gene
expression as found in the majority (85%) of EBV-positive Burkitt lymphomas (BL); Wp-restricted latency
(Wp Latency), as found in a minority (15%) of EBV-positive BLs (termed Wp-BL); and Latency II EBV
gene expression, which is found in EBV-positive Hodgkin lymphoma (HL) as well as the EBV-associated
epithelial malignancies, nasopharyngeal carcinoma (NPC) and gastric carcinoma (GC). Latent proteins
(EBNA1, EBNA2, EBNA3A, EBNA3B, EBNA3C, EBNA-LP, BHRF1, LMP1 and LMP2A/B) are shown
in blue. Non-coding RNAs (EBERs, miR-BHRF1s and miR-BARTs) are shown in red, and selected latent
promoters (Cp, Wp and Qp) are shown in green. Connecting lines denote splicing patterns, whilst blocks
indicate exons. In Wp-BL, EBNA-LP is truncated due to a genomic deletion and is therefore denoted
as t-EBNA-LP.
2.1. Dynamics of Early Infection
Upon infection of resting B cells, EBV gene expression, driven by host cell RNA polymerase
II, begins almost immediately; the Wp promoter that drives early latent gene expression reaches
maximal activity around 8–12 h post-infection (PI). These long and differentially spliced Wp-transcripts
preferentially encode EBNA-LP, EBNA-2 and BHRF1 [25,26]. The nuclear antigens (EBNAs-LP and -2)
then transactivate the Cp and LMP promoters [27–29], leading to the expression of EBNA1, EBNA3A,
-3B and -3C and LMP1, 2A and 2B, respectively, which reach peak expression at 2–3 days PI [25,30].
Importantly however, there is a delay between maximal expression of latent transcripts and the
proteins they encode. The EBNA2, EBNA-LP and BHRF1 proteins reach levels comparable to those in
established LCLs at around 72 h [25,31], whereas LMP1 protein is low or undetectable until 5 days
PI. [19,32]. Expression of EBV non-coding RNAs is similarly delayed: they are not detected at
appreciable levels until several days after infection (Figure 2). Many of these EBV genes are reported
to have roles in cell proliferation and/or survival.
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Figure 2. Temporal patterns of latent gene expression during growth transformation of primary 
resting B cells. Schematic showing the general transcription patterns of different classes of latent EBV 
genes during in vitro growth transformation of primary, resting B cells. Wp-derived transcripts 
preferentially give rise to BHRF1, EBNA2 and EBNA-LP in order to kick start cells into cycle, though 
they also encode EBNA-3A, -3B and -3C (EBNA3s) and EBNA1. Cp can encode all EBNAs and BHRF1. 
NC RNAs include EBER1, EBER2, miR-BARTs and miR-BHRF1s. Data are cumulative estimations 
based on transcriptional data published by Tierney et al. [33], Shannon-Lowe et al. [30], and Amoroso 
et al. [24]. 
2.2. EBNA-2 and EBNA-LP 
EBNA-2 and EBNA-LP are the first proteins to be expressed following infection of B cells. 
EBNA2 is a functional mimic of cellular Notch [34–36] and is responsible for kick-starting cell cycle 
activation through its RBP-Jκ-mediated pleiotropic effects on chromatin organisation and gene 
regulation [37–40]. Therefore, it is not surprising that EBNA2 expression is essential for B cell 
transformation [41]. EBNA2 can also inhibit intrinsic cell death through interactions with, and 
upregulation of, cellular proteins. EBNA-2 can directly bind and inhibit the orphan nuclear receptor 
Nur77 [42,43] which is reported to bind and modulate the function of several pro-survival BCL-2 
family members [44]. Additionally, EBNA-2 expression was shown to upregulate the pro-survival 
BCL-2 family protein, BFL-1/A1, at the mRNA level via binding to RBP-Jκ/CBF1 [45] and co-
ordinately downregulate the BCL-2 family death inducer, BIK [46]. More recently, EBNA-2 has also 
been shown to contribute to the activation of MYC, that can both increase proliferation and sensitise 
cells to apoptosis, through long-range interactions [47]. EBNA-LP, the transcriptional coactivator of 
EBNA2 [48], is essential for efficient B cell transformation [49–51], but has so far had few survival 
functions attributed to it in the context of LCLs. Interestingly, however, it has been reported that 
EBNA-LP (also called EBNA-5), can bind Fte-1/S3a, which is able to contribute to cell survival by 
interacting with PARP [52]. Another study found that EBNA-LP could interact with p14ARF in a yeast 
2-hybrid system and colocalised with p14ARF and p53 transcripts in LCLs [53]. EBNA-LP has also been 
shown to interact with BCL-2 in the presence of HAX-1 in pull down experiments using glutathione 
S-transferase fusion proteins in the primate kidney cell line, COS-7 [54]. Therefore, the possible 
survival functions of EBNA-LP during transformation warrant further investigation. 
2.3. EBNA-3A, -3B and -3C 
The EBNA-3s are a family of three large proteins (3A, 3B, 3C), which likely arose by gene 
duplication, that predominantly function as regulators of host cell and virus transcription. Like 
EBNA-2, the EBNA-3 proteins do not bind DNA directly, but instead transactivate or repress gene 
expression via interactions with transcription factors, such as RBP-Jκ, for which all four EBNAs 
Figure 2. Temporal patterns of latent gene expression during growth transformation of primary resting
B cells. Schematic showing the general transcription patterns of different classes of latent EBV genes
during in vitro growth transformation of primary, resting B cells. Wp-derived transcripts preferentially
give rise to BHRF1, EBNA2 and EBNA-LP in order to kick start cells into cycle, though they also encode
EBNA-3A, -3B and -3C (EBNA3s) and EBNA1. Cp can encode all EBNAs and BHRF1. NC RNAs
include EBER1, EBER2, miR-BARTs and miR-BHRF1s. Data are cumulative estimations based on
transcriptional data published by Tierney et al. [33], Shannon-Lowe et al. [30], and Amoroso et al. [24].
2.2. EBNA-2 and EBNA-LP
EBNA-2 and EBNA-LP are the first proteins to be expressed following infection of B cells.
EBNA2 is a functional mimic of cellular Notch [34–36] and is responsible for kick-starting cell
cycle activation through its RBP-Jκ-mediated pleiotropic effects on chromatin organisation and
gene regulation [37–40]. Therefore, it is not surprising that EBNA2 expression is essential for B
cell transformation [41]. EBNA2 can also inhibit intrinsic cell death through interactions with,
and upregulation of, cellular proteins. EBNA-2 can directly bind and inhibit the orphan nuclear
receptor Nur77 [42,43] which is reported to bind and modulate the function of several pro-survival
BCL-2 family members [44]. Additionally, EBNA-2 expression was shown to upregulate the
pro-survival BCL-2 family protein, BFL-1/A1, at the mRNA level via binding to RBP-Jκ/CBF1 [45] and
co-ordinately downregulate the BCL-2 family death inducer, BIK [46]. More recently, EBNA-2 has also
been shown to contribute to the activation of MYC, that can both increase proliferation and sensitise
cells to apoptosis, through long-range interactions [47]. EBNA-LP, the transcriptional coactivator of
EBNA2 [48], is essential for efficient B cell transformation [49–51], but has so far had few survival
functions attributed to it in the context of LCLs. Interestingly, however, it has been reported that
EBNA-LP (also called EBNA-5), can bind Fte-1/S3a, which is able to contribute to cell survival by
interacting with PARP [52]. Another study found that EBNA-LP could interact with p14ARF in a
yeast 2-hybrid system and colocalised with p14ARF and p53 transcripts in LCLs [53]. EBNA-LP has
also been shown to interact with BCL-2 in the presence of HAX-1 in pull down experiments using
glutathione S-transferase fusion proteins in the primate kidney cell line, COS-7 [54]. Therefore, the
possible survival functions of EBNA-LP during transformation warrant further investigation.
2.3. EBNA-3A, -3B and -3C
The EBNA-3s are a family of three large proteins (3A, 3B, 3C), which likely arose by
gene duplication, that predominantly function as regulators of host cell and virus transcription.
Like EBNA-2, the EBNA-3 proteins do not bind DNA directly, but instead transactivate or repress
gene expression via interactions with transcription factors, such as RBP-Jκ, for which all four EBNAs
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compete (reviewed in [55]). Although they share less than 30% amino acid identity, EBNA-3A, -3B
and -3C exhibit structural similarity [56,57] and display some overlap in terms of some of the loci
and processes that they regulate. Interestingly, only EBNA-3C is essential for B cell transformation;
although B cells infected with viruses lacking EBNA-3A display a growth impairment and readily
undergo apoptosis [58–60]. In contrast, EBNA-3B is dispensable for B cell transformation and LCLs
generated with an EBNA-3B knock-out (KO) virus exhibit comparable resistance to apoptosis as those
transformed with wild-type (wt) EBV [61,62]. Extensive analyses of cells infected with EBNA-3 KO or
conditional viruses that encode estrogen-inducible EBNA-3 proteins revealed that EBNA-3A and -3C
are able to co-operatively downregulate the apoptosis inducing, BH3-only protein BIM [63–65] as well
as the tumour suppressors p16INK4a and p14ARF [58,59,66–69] through epigenetic silencing. EBNA-3C
can also reportedly interact with p53 as well as binding and stabilising the p53 regulators, ING4, ING5,
MDM2 and Gemin3 [70–72]. Although the downregulation of BIM and p14ARF by EBNA-3A and -3C
occurs through epigenetic silencing at their transcriptional start sites (TSS) [59,63,64,66,68], the EBNA3
proteins regulate many other genes by long range interactions up to 50 kb away from a TSS [69,73].
It is estimated that collectively, the EBNA-3 proteins can bind more than 7000 sites on the cellular
genome; therefore, it is likely that other cell survival genes regulated by the EBNA3s will be identified
in the future.
2.4. EBNA-1
The primary function of EBNA-1 protein is to tether EBV episomes onto host cell chromatin
to ensure the viral DNA is replicated during cell mitosis. Therefore, EBNA1 expression is essential
for the maintenance of latent infection [74–76]. There is evidence that EBNA-1 may also affect the
survival of EBV-infected cells, but interestingly the literature in this regard is conflicting, with reports
that EBNA1 is both pro- and anti-apoptotic in function [77]. EBNA-1 has been shown to cause
genomic instability by triggering reactive oxygen species production and the DNA damage response
(DDR) [78,79]. Conversely however, EBNA1 may stabilise p53 to counteract DDR by binding to the p53
regulator, USP7 [80] and further block downstream caspase activation by upregulation of Survivin [81].
EBNA-1 reportedly binds and regulates the promoters of many other cellular genes but the functional
consequences and implications of these interactions for cell survival are not yet fully elucidated [82–85].
2.5. LMP1
LMP1 promotes cell growth and survival and is essential for B cell transformation [86,87].
Functionally, it is a CD40 homologue [88,89] that constitutively mimics cellular TNF signalling through
its two cytoplasmic signalling domains, CTAR1 and CTAR2 (sometimes referred to as TES1 and
2) [90–92]. CTAR1 binds TRAF and consequently stimulates the non-canonical NF-κB cascade via
p100/RelB [93,94], whilst CTAR2 activates both the canonical pathway and JNK signalling through
binding to TRADD, IRF7 and BS69 and downstream activation of IKKβ [95–97]. Consequently,
LMP1 upregulates NF-κB responsive BCL-2 pro-survival proteins, including BCL-2, MCL-1 and
BFL-1/A1 [98–102] and the cyto-protective, JNK-regulated chemokines, CCL3 and CCL4 [103].
Additionally, a recent genome-wide CRISPR/Cas9 loss-of-function screen in BLs and LCLs in vitro
identified another previously identified NF-κB/LMP1 transcriptional target, cFLIP [104], which can
suppress the extrinsic apoptotic and necroptosis pathways, as critically important for the survival of
LCLs [105]. Conversely, LMP1 has also been shown to be capable of inducing Fas-mediated apoptosis
in B cells with coincident cleavage of Caspase 8 and BID [106,107]. Interestingly, this pro-death activity,
which is independent of the CTARs and instead maps to the transmembrane region is masked when
LMP1 is expressed at moderate levels and is only evident where LMP1 is over-expressed [98].
2.6. LMP2A and LMP2B
LMP2A and 2B are expressed from a series of complex, overlapping transcripts, each driven by its
own unique promoter that, like the LMP1p, are transactivated by EBNA-2 during transformation [108–110].
Viruses 2017, 9, 339 6 of 34
LMP2A, like LMP1, is a constitutive mimic of cellular receptor signalling. Whereas LMP1 is a CD40
homologue, LMP2A emulates B cell receptor (BCR) cross-linking, therefore during infection of B cells,
the LMPs are able to recapitulate the signals essential for normal B cell development and function [1].
In vitro, LMP2A is dispensable for the initial transformation of B cells [111–114], but has been shown to
provide critical ongoing cell survival signals, including inhibition of TGF-β-associated apoptosis through
activation of PI3K/Akt/mTOR [105,115,116]. Furthermore, LMP2A can rescue “crippled” B cells; that is
germinal centre B cells with Ig mutations that consequently lack a functional BCR, and so would otherwise
rapidly undergo programmed cell death [117,118]. LMP2A function is dependent on recruitment of and
interaction with Src family tyrosine kinases and LMP2A must be phosphorylated at residues Y74 and
Y85 by Syk in order to activate pro-survival PI3K/Akt/mTOR signalling [119–121]. LMP2B shares most
of its exons with LMP2A, but lacks the N-terminal Syk domain [110,122]. Much less is known about
the function of LMP2B compared to LMP2A, but it has been shown to functionally oppose LMP2A and
instead may potentiate LMP1 signalling in order to fine tune signalling in infected B cells [123].
2.7. BHRF1 and BALF1
A number of viruses, including EBV, encode homologues of cellular pro-survival BCL-2 family
proteins in order to evade apoptosis triggered as part of the anti-viral response. These viral BCL-2 proteins
(vBCL-2s) vary in the degree of similarity they display to their cellular counterparts in terms of sequence,
structure and function (reviewed in [124]). Although most vBCL-2 proteins are regarded as regulators of
the intrinsic apoptosis pathway, some also regulate additional cellular processes [125–128].
EBV encodes two BCL-2 homologues, called BHRF1 and BALF1. These viral proteins have long
been known to be expressed at high levels during lytic cycle, presumably to keep host cells alive to
ensure efficient virus replication. They have more recently been shown to also be expressed during
the early stages of primary B cell infection in vitro: BHRF1 and BALF1 cDNAs can be detected by
day 1 PI [33,129]. Recombinant viruses lacking either BHRF1 or BALF1 are able to transform resting
B cells in vitro, but are slightly impaired. However, the loss of both BHRF1 and BALF1 completely
abrogates the ability of the virus to transform B cells, suggesting redundancy in their function in this
regard [129]. Whilst BHRF1 protein has been shown to also be constitutively expressed in established
latent LCLs [19], no antibody to BALF1 exists and therefore the expression of BALF1 protein in
LCLs has not been examined. Therefore, although BALF1 transcripts can be detected at low levels
in LCLs [33], it is not known whether these arise from a small number of lytically infected cells or,
like BHRF1, are expressed during latency.
Both BHRF1 and BALF1 contain all four of the functionally important BCL-2 homology domains,
BH1-4 [130,131]. BHRF1 is relatively well-characterised: its BH3 binding groove exhibits 25% amino acid
sequence similarity to cellular BCL-2 [132] and structurally most closely resembles BCL-xL. Like cellular
BCL-2 pro-survival proteins, BHRF1 protein has a hydrophobic groove formed by α-helices 2–5 of its
7-helix bundle [133], into which BH3 ligands can bind. BHRF1 is potently anti-apoptotic in vitro and can
confer protection to different cell types from a wide variety of death-inducing stimuli [19,131,133–142].
Furthermore, ectopic expression of BHRF1 from a retrovirus vector in Eµ-Myc mouse lymphoma cells
in vivo can confer protection from DNA damaging chemotherapeutics [133].
The mechanism by which BHRF1 confers apoptosis protection is through binding and sequestration
of cellular pro-apoptotic proteins. BHRF1 can bind to the cellular BH3-only proteins BIM, PUMA and
BID and the apoptosis effector (or executioner) protein, BAK [124] (see Figure 3). One report attributes all
apoptosis protection to the ability of BHRF1 to bind BIM [134,135], however work from our laboratory has
shown that BHRF1 can also protect in the absence of BIM (Fitzsimmons et al. manuscript in preparation).
By comparison to BHRF1, BALF1 is much less well characterised. BALF1 was identified as a BCL-2
homologue by predicted structural similarity to known vBCL-2s, and though it has been shown to
modulate apoptosis, it remains controversial as to whether it promotes or inhibits cell death [130,143].
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Figure 3. Binding specificities and affinities of BCL-2 family members and EBV BHRF1. (a) 
Interactions between pro-survival and pro-death BCL-2 family members. Reported as Kd in nM as 
determined by surface plasmon resonance (BCL-2, BCL-xL and MCL-1) or isothermal calorimetry. 
Sources were: BCL-2 and BCL-xL [144–146], MCL-1 [144], A1 [147] and BHRF1 [124,133]. Colour 
coding was applied as follows: green 1–10 nM, pale green 11–50 nM, yellow 51–100 nM, pale orange 
101–1000 nM, orange 1001–2000 nM, red 2000–100,000 nM. (b) Ribbon structure representation of 
BHRF1 (blue) bound to the BH3 domain of BAK (red). This graphic was prepared using the UCSF 
Chimera software package (developed by the Resource for Biocomputing, Visualization, and 
Informatics at the University of California, San Francisco [148], supported by NIGMS P41-GM103311) 
using pdb accession code 2XPX [133]. 
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Figure 3. Binding specifi ties and ffinities of BCL-2 family me bers and EBV BHRF1. (a) Interactions
between pro-survival and pro-de th BCL-2 family members. Reported a Kd in nM determined
by surface plasmon resonance (BCL-2, BCL-xL and MCL-1) or isothermal calorimet y. Sources we e:
BCL-2 and BCL-xL [144–146], MCL-1 [1 4], A1 [147] and BHRF1 [12 ,133]. Colour coding was applied
as follows: green 1–10 nM, pale reen 11–50 n , yellow 51– 00 nM, pale orange 101–1000 nM, orange
1001–2 , red 2000–1 0,000 nM. (b) Ribbon structure representation of BHRF1 (blue) bound t the
B 3 domain of BAK (red). This graphic was prepared using the UCSF Chimera software package
(developed by the Resource for Biocomputing, Visualization, and Informatics at the University of
California, San Francisco [148], supported by NIGMS P41-GM103311) using pdb accession code 2XPX [133].
2.8. Non-Coding RNAs
A number of viral non-coding RNAs are expressed during transformation. Some of these transcripts
are reported to egulate cell death during transformation an latency; howeve , their functions are l s
well under tood than those f the latent proteins. The Epstein–Barr virus encoded RNAs (EBERs) are two
highly transcribed small (~170 nt) nuclear RNAs (EBER1 a d EBER2) [23,149] whose function(s) remain
somewhat enigmatic. The EBERs are abundantly expressed in established LCLs but they are not detectable
until aro d 72 h after infecti n of primary B cells [150]. EBV also encodes around 40 mature microRNAs
(miR /miRNAs), derive from 25 precursor (pre-miRNA) trans ripts [151–154]. Mi roRNAs selectively
bi d to and inhibit mRNAs by causing transcript instability, degradation, or impai d t anslation. Similar
to cellular miRNAs, EBV encoded pre-miRNAs are processed by Drosher and Dicer into mature miRNAs
a d incorporated into the RISC complex, which then binds the target transcript to which the miRNA
confers specificity by virtue of its 6 nt ‘seed s quence’ (reviewed in [155,156]). The EBV miRNAs can
be divided into two familie , according to their osition within the viral ge ome. The BHRF1 m RNAs
re ide either side of the BHRF1 ORF, whereas the BART family of miRNAs are derived from the BamHI
A rightward transcript (BARTs). Despite abundant BHRF1 and BART primary transcr pt xpression at
early time points during ransformation, processing of thei derivative miRNAs is delayed, peaking at
a ound 72–120 h PI [24].
2.8.1. EBERs
The EBERs are ubiquitously expressed from their own viral promoters in all forms of latent
infection. There have been conflicting reports regarding the ability of EBER-KO recombinant viruses
to transform B cells, although it should be noted that no previous studies have found the EBERs to
be essential for transformation. Interestingly, different groups have used different strains of EBV in
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their experiments, suggesting that the role of the EBERs in transformation may be context dependent
and influenced by the other co-expressed viral proteins. Swaminathan et al. used the transformation
incompetent P3HR1 virus strain, which harbours a large genomic deletion spanning the EBNA2 locus,
and recombined it with a large fragment of the prototypic B95.8 EBV that was either wt for or lacked
the EBER locus (lacking both EBER1 and EBER2). The resulting recombinant wt or EBER-KO EBVs
were both transformation competent [157] and were found to give rise to LCLs that grew at the same
rate as wt EBV-derived LCLs [158]. However, an alternative EBER-KO virus made in the Akata virus
strain was found to be less than 50% as efficient at transforming B cells than wt virus and the resulting
LCLs exhibited a growth impairment in limiting dilution assays compared to wt comparators [159].
When expression of the individual EBERs was restored in this background, it was found that an
EBER2 knock-in (KI) virus behaved like wt Akata virus, but the EBER1-KI (lacking EBER2) virus was
as impaired as the double EBER-KO, suggesting that only EBER2 is important for transformation
and that EBERs play distinct, non-overlapping roles in this process [160]. Recently however, it has
been shown that EBER-KO viruses (both double and single KOs) made in the B95.8 background
could transform B cells with equal efficiency to wt virus [161]. It may be relevant that this study
used adult PBMCs as a source of B cells, whereas the Akata-derived virus studies were carried out
on cord blood-derived cells. Interestingly, the B95.8 study identified two apoptosis-related genes as
EBER targets by microarray analyses. Deletion of EBER1 led to a 6-fold downregulation of GAS2,
whilst EBER2-KO cells showed around a 40-fold reduction in SASH1 [161]. Both GAS2 and SASH1
are reported to be downstream targets of Caspase 3 and have been shown to contribute to apoptosis
induction [162,163]. Somewhat counterintuitively, this suggests that EBERs may prime LCLs for cell
death, although further mechanistic studies have yet to be published.
2.8.2. BHRF1 microRNAs
The BHRF1 family of miRNAs consists of one miRNA encoded upstream (miR-BHRF1-1) and
two miRNAs encoded downstream (miR-BHRF1-2 and miR-BHRF1-3) of the BHRF1 ORF. During viral
transformation of B cells, the BHRF1 miRNAs are processed from the polycistronic Wp and Cp-driven
latent transcripts that encode the EBNA proteins and latent BHRF1 protein [164–166]. EBV genomes
deleted for individual miR-BHRF1s show a mild impairment in transformation compared to wt controls
and the contribution of these miRNAs was found to be cumulative. Viruses lacking miR-BHRF1-2
(∆2) and -3 (∆3) were the most transformation deficient, whereas viruses deleted for miR-BHRF1-1 (∆1)
transformed B cells almost as efficiently as wt EBV [167]. Accordingly, when all three BHRF1 miRNAs
were deleted, the resulting ∆123 viruses showed a marked transformation defect, which was attributed to
increased apoptotic cell death early after infection. Additionally, the resultant LCLs exhibited reduced
S-phase entry and proliferated less well than controls [168,169]. In humanised NSG mice, animals infected
with the ∆123 virus displayed lower viral loads at early time points after infection compared to mice
infected with wt virus, but there was no difference in tumorigenic potential between ∆123 and wt
EBV [170]. Interestingly, it was shown that ∆miR-BHRF1 LCLs exhibit lower expression levels of BHRF1
transcripts and protein as well as other latent transcripts [31,168], indicating that at least some of the effect
of miR-BHRF1 deletions were indirect. Indeed, whilst EBV lacking BHRF1 protein transformed around
50% as efficiently as wt controls, viruses lacking both BHRF1 protein and miRNAs were incapable of
transforming B cells [31,129]. These results suggest that the BHRF1 miRNAs and BHRF1 protein function
cooperatively to control cell cycle entry and apoptosis during primary infection.
Other than regulating the expression of the pro-survival, BHRF1 protein, it is also somewhat
unclear how the BHRF1 miRNAs might further regulate apoptosis. This is, in part, because it can be
difficult to experimentally confirm bona fide miRNA targets and because viral miRNAs sometimes
display unique functional features compared to their cellular counterparts, such as tolerating ‘bulges’
in their mRNA seed region binding sites [165,171] (and reviewed in [172]). What is known is
that EBV miRNAs bind and may contribute to the regulation of hundreds of viral and cellular
transcripts, many of which have been ascribed roles in cell survival. As well as being primarily
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responsible for the regulation of BHRF1 protein, miR-BHRF1-2 has also been found by luciferase
reporter assays to inhibit expression of the apoptosis-related genes, BACH1 and KDM4B [165],
whilst miR-BHRF1-3 has been found to downregulate PTEN protein, thereby reducing cell cycle
progression and, through the PI3K/Akt pathway, apoptosis [31]. Interestingly, although PTEN and
BACH1 are both pro-apoptotic [173,174], KDM4B (also called JMJD2B) is a gene induced by p53 that
can repress the induction of select p53 targets including p21, PIG3 and PUMA and thereby suppress
cell cycle arrest and cell death [175]. This suggests that BHRF1 miRNAs might function to modulate
the cell death response.
2.8.3. BART microRNAs
The BamHI A region, which is transcriptionally active in several EBV-associated malignancies,
has long been known to give rise to a complex variety of transcripts driven from two promoters
(P1 and P2) [176–179]. It took until 2004 to discover that introns from these transcripts give rise to
microRNAs [20]. It had previously been proposed that these transcripts encoded proteins [180–182],
but whilst they could be transcribed and investigated in vitro, there was little evidence for the existence
of BamHI A-derived proteins in EBV-positive cell lines [183,184]. The BART miRNAs are reported to
regulate a number of cell survival and growth-related transcripts. However, the majority of studies
linking BART miRNAs to survival were carried out in nasopharyngeal carcinoma (NPC) where they
are highly expressed. Although the BART miRNAs are expressed at lower levels in LCLs compared to
epithelial cells, they still number thousands of copies per cell in total, and are consistently detected in
all types of latency [166]. Interestingly, the expression of individual BART miRNAs exhibits hierarchy,
and the less abundant miRNAs are only present at tens of copies per cell in LCLs [24,165].
The prototypic EBV strain, B95.8, from which many of the widely used recombinant EBVs are
derived, harbours a large (12 kbp) deletion compared to other EBV isolates [185,186], and consequently
lacks most of the BART microRNAs. The readiness of the B95.8 strain and its recombinant derivatives
to transform resting B cells suggests that the BART miRNAs are dispensable for transformation.
Accordingly, Seto et al. found that a recombinant EBV lacking both BART and BHRF1 miRNAs
was equally as efficient in transformation assays as a virus deficient in only BHRF1 miRNAs [169].
However, another study found that two B95.8 derivative viruses that had been ‘repaired’ for the
BART miRNA sequences using different strategies both caused more efficient outgrowth of B cells PI.
Interestingly, there was greater variation between the two different miR-BART repaired recombinant
virus strains than between the B95.8 strain and the less efficient repaired strain [187].
In order to identify targets of EBV miRNAs, Dolken et al. carried out immunoprecipitation
of RISC complexes (containing miRNAs and their targets) in two EBV-infected BL cell lines and
then identified the target mRNA using microarray analyses. They showed that miR-BART3 and
miR-BART16 downregulated IPO7 and TOM22 transcripts, respectively [188], both of which encode
transport proteins and are reported to have pro-apoptotic functions [189,190]. Another group used
a similar technique to investigate the cellular targets of EBV-encoded miRNA in Latency III BL
cells (expressing all of the miR-BARTs), but first crosslinked the RISC complexes and RNA species
together by UV-irradiation [191]. In this study, Riley et al. identified 132 apoptosis-associated genes
as miR-BART targets, notably: the previously reported PTEN, IPO7 and TOM22, in addition to the
EBV oncogenes, LMP1 and BHRF1; multiple pro-death BCL-2 family members, PUMA, BAK, BID,
PMAIP1 (NOXA), BIM, and pro-survival MCL1; as well as CASP2, CASP3 and MYC. Only a small
subset of these targets was validated in luciferase reporter assays [192]. Finally, a third group used an
alternative method to crosslink miRNAs and their targets together in B95.8-derived LCLs (expressing
only five BART miRNAs), followed by RNA sequencing to identify the targets. They also reported a
significant enrichment among their hits for genes that can directly or indirectly influence cell survival
including MCL1; the apoptosome component, APAF1; and the miRNA processing factor, DICER [165].
The use of RNA sequencing technologies has also led to the identification of a large number of
novel EBV transcripts in latently infected cells [193], some of which are likely to turn out to be bona
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fide, functional ncRNAs [194]. Therefore, it is possible that the repertoire of EBV-encoded ncRNAs
that regulate cell survival may expand in the near future.
3. Lytic Cycle Genes and Transformation
Although EBV is usually found to be latent in infected cells both in vivo and in vitro, the virus
must periodically enter into the lytic cycle to generate infectious viral progeny to infect new cells
within the host and thereby guarantee persistence and dissemination into new hosts. In vivo, the lytic
cycle is thought to occur in terminally differentiated plasma cells and epithelial cells (reviewed in [195]).
In vitro, replication occurs sporadically in a small population of cells in latent LCLs and tumour cell
lines. Although the frequency and rate of lytic cycle activation can vary between cell lines and types,
usually around 1–5% of cells are found to express the lytic cycle marker gene, BZLF1, in LCL cultures
at any given time [196]. The lytic cycle is initiated by expression of BZLF1 and BRLF1, the ‘immediate
early’ lytic genes, and then proceeds in two further phases of virus gene expression. BZLF1 binds
and activates promoters containing Z-response elements (ZREs) [197,198], and seems to preferentially
bind ZREs that are highly methylated [199,200]. BRLF1 can enhance transcription directly, by binding
DNA at GC-rich promoter sequences to activate transcription [201], or indirectly, where DNA-binding
is not necessary [202,203]. These transcription factors stimulate the expression of a second wave of
lytic-associated viral genes, known as the early lytic genes. Early genes include those required for
viral DNA synthesis, inhibition of apoptosis and immune evasion. Once the viral DNA has replicated,
the late lytic genes are expressed, many of which encode structural or packaging elements of the virus.
The lytic cycle is also closely linked with cell death since the thousands of EBV particles that are
produced eventually cause any cell undergoing lytic replication to lyse, releasing infectious virus [204,205].
Conversely, EBV must also ensure that cell death is not triggered too early after lytic cycle activation
to allow time for progeny to be synthesised and packaged efficiently. It is unsurprising then, that EBV
lytic genes have been ascribed both pro- and anti-apoptotic functions. For example, BZLF1 indirectly
induces cell death via inhibition of the NF-κB family protein, p65 [206] and downregulation of CD74 [207].
Conversely, the viral BCL-2 protein, BHRF1, has been shown to directly block BZLF1 toxicity, which has the
dual consequences of blocking apoptosis and contributing to the evasion of NK cell recognition and killing
of BZLF1-expressing EBV-positive B cells [208]. Another group found that induction of EBV-positive
cell lines into the lytic cycle also induced cell death in cell cultures. Interestingly however, the lytic
BZLF1-positive cells were resistant to death compared to the cells that remained latent, further suggesting
that EBV expresses potent anti-apoptotic genes upon lytic reactivation. Furthermore, cells that were
treated with acyclovir (ACV) to specifically block late lytic cycle EBV gene expression exhibited an
increased propensity to undergo apoptosis, suggesting that both early and late lytic genes contribute
to cell survival during virus replication [209]. The BH3-only BCL-2 family protein, BIM, has also been
shown to be downregulated in a two-step fashion during lytic cycle, suggesting that it is a common target
for both early and late EBV lytic genes [210].
In primary B cells, a number of lytic-cycle-associated EBV genes have been shown to be transcribed
early during transformation (1–4 days PI.) including BZLF1, BRLF1, BCRF1 (viral IL-10), BALF1, BHRF1
and BMRF1 in the absence of any production of infectious virions [129,199,211,212]. Conversely, inhibition
of apoptosis by miR-BART20-5p has been shown to indirectly inhibit the lytic cycle, suggesting that latent
apoptosis regulatory genes may also play a role in EBV replication [213]. There also remain a number
of EBV genes that are assigned as ‘lytic’ about which almost nothing is known. LF3, for example, is
classified as a lytic gene since it is robustly transcriptionally upregulated during the lytic cycle [214].
However, RNA-sequencing and quantitative PCR studies showed that LF3 is also highly transcribed
in largely latent cell lines [33,193]. Together, these studies demonstrate the interplay between apoptosis
and the EBV lytic cycle and raise the possibilities that (1) the definition between latency and lytic cycle
may be less well defined than current dogma dictates, (2) some lytic genes may regulate cell death and
(3) poorly described EBV genes may contribute to cell death regulation during latency as well as lytic
cycle. Further work is required to better understand the role of lytic cycle genes in the regulation of cell
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death during transformation and in malignancy in order to determine whether these processes might be
useful therapeutic targets for EBV-associated diseases.
4. Cooperative Cell Death Inhibition by EBV
4.1. Counteracting the DNA Damage Response
A number of studies have provided insight into the interplay between latent proteins and host cell
survival pathways through analyses of early infection (the first 7–10 days PI.) during the establishment
of latency (Figure 2). EBV infected B cells begin to proliferate rapidly at around 4 days PI. [32,215–217],
when the Wp transcript-encoded EBNA and BHRF1 proteins are maximally expressed [19,25,30,31].
Coincident with entry into cell cycle, activated lymphoblasts initiate the DNA damage response,
including robust upregulation of p53 and related pro-apoptotic genes [216,218–220]. Many oncogenic
viruses (including SV40, HPV and adenovirus) must directly inactivate p53 in order to transform
cells (reviewed [221]), yet in the case of EBV, p53 signalling remains intact in established LCLs [218].
However, DNA damage signalling and p53-induced apoptosis must be countered in order for EBV to
transform resting B cells [222]. Furthermore, CRISPR screens have revealed that the p53 inhibitors,
MDM2 and MDM4, remain critical for the ongoing survival of established LCLs [105]. Despite
markers of DNA damage including γH2AX and chromosomal abnormalities appearing within the first
seven days following infection [216,223], few cells are found to undergo apoptosis at these early time
points [32,215,217]. It is hypothesised that EBNA3C is largely responsible for preventing p53-driven
apoptosis during early time points PI. Since it has been reported to bind and/or stabilise several p53
inhibitors including Gemin3, Aurora B kinase, ING4, ING5 and MDM2 [70,72,224–226] and also to
repress the p53 activator p14ARF [66]. Interestingly, inhibition of p53-mediated apoptosis also remains
essential long-term as a CRISPR screen has recently shown that MDM2 and MDM4 are critical for the
survival of established LCLs [105].
Following activation of p53, cell death proceeds through the BCL-2 family/intrinsic pathway to
apoptosis, via p53-induced upregulation of the BH3-only proteins PUMA and NOXA. These BH3-only
proteins initiate cell death by binding to the BCL-2 pro-survival proteins, thereby releasing the
executioners of apoptosis BAX and BAK. These proteins form pores in the mitochondrial outer
membrane (MOMP) which commits the cell to apoptosis. BAK and BAX can also be directly activated
by the BH3-only proteins, BIM, tBID and PUMA, though only PUMA is upregulated by p53 activation
(reviewed in [227]) (see Figure 4). Many human viruses have evolved strategies to interfere with
the intrinsic apoptotic pathway (reviewed in [228]). EBV itself encodes two multi-domain BCL-2
homologues, BHRF1 and BALF1, as discussed earlier. BHRF1 may contribute to the blockade of
p53-dependent DDR signalling as it is able to bind and inhibit pro-apoptotic PUMA, [133] and
can efficiently inhibit DNA-damage-induced cell death in the absence of any other EBV genes
(Fitzsimmons et al. in preparation). LMP1 has been shown to block apoptosis through upregulation
of cellular BCL-2 pro-survival proteins [98,99,101,102]. As discussed throughout this review, EBNA1,
EBNA2, the EBNA3s, and both families of EBV miRNAs, also regulate a variety of different BCL-2
family members and associated intrinsic apoptosis regulatory elements. Consistent with this complex
regulation by multiple EBV genes, a recent study showed that EBV-infected lymphoblasts and LCLs
do not rely on any single BCL-2 family member for survival. Instead, the sensitivity of EBV-infected
cells to BH3-only proteins changes throughout the process of growth transformation [32].
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combinatorial and/or redundant effects of EBV genes in apoptosis regulation in a given disease setting
is imperative to inform therapeutic treatments. To this end, the recent development of new methods
such as CRISPR/Cas9 to quickly and precisely genetically modify the EBV genome within infected
cells [232] will be central for dissecting the cooperation between EBV genes in cell death regulation.
4.3. Cooperative Inhibition of Apoptosis in Malignancy
EBV is known to contribute to various forms of malignancy of lymphoid and epithelial cell origin,
together accounting for around 200,000 new cancer diagnoses annually [4]. Although the role of the
virus is not fully understood in these EBV-associated cancers, there is a large body of evidence to
suggest that the virus contributes to the inhibition of cell death in many cases. Whilst the transformation
of resting B cells into continuously proliferating LCLs is a useful model for EBV infection, the pattern
of latent gene expression seen in LCLs (Latency III) is rarely seen in EBV-positive tumours. If fact,
it is usually only detected in patients who are immunocompromised, for example in EBV-driven
post-transplant lymphoproliferative disease (PTLD) or in HIV-positive individuals [1]. In these cases,
where the immunological imperative for restricted latency is relieved, the cooperative contribution of
the Latency III genes is likely to largely reflect those seen in LCLs. Accordingly, although relatively
few mechanistic studies exist on EBV-mediated apoptosis inhibition in PTLD, there are reports that
key genes implicated in cell death regulation in LCLs, such as Syk, IL10 and BIM, are also deregulated
in this malignancy [233–235]. In all other known EBV-associated malignancies, EBV usually adopts
more restricted and less immunogenic latencies that vary among different EBV-associated cancers
(Figure 1). This means that the most abundant or functionally important EBV targets for therapy may
differ among different EBV-associated malignancies. Another important consideration in this regard is
that there is evidence that EBV genes work together to cooperatively modulate cell survival pathways
in diverse EBV-associated cancers, even in BLs, which exhibit the most restricted form of EBV latency
(Latency I). Whilst this raises the possibility that targeting a single EBV protein in malignancy may
be ineffective, it does suggest that therapies which disrupt viral hijacking of these critical pathways
might be of clinical benefit across multiple EBV malignancies. Here, we review in detail the role of
EBV genes in the cooperative inhibition of apoptosis in BL.
5. Burkitt Lymphoma (BL)
The frequency and geographical incidence of BL in malarial endemic regions of sub-Saharan
Africa is consistent with an infectious aetiology and this led to the identification of BL as the first
cancer to be associated with EBV infection. Accordingly, EBV was found to reside in more than 95%
of BLs in high incidence or endemic BL (eBL) areas. BL also occurs worldwide at a lower incidence,
and in these cases, known as sporadic BLs (spBL), EBV is found in 15–85% of tumours, varying by
geographical region [236–239].
5.1. c-MYC
Common to all cases of BL is the hallmark reciprocal translocation between the c-MYC oncogene
and a constitutively active immunoglobulin (Ig) gene promoter/enhancer [240–242]. This unchecked
overexpression of the c-MYC protein reprograms cells for maximum proliferative capacity [243–245].
Conversely however, c-MYC also sensitises cells to apoptosis under conditions of stress [246].
Therefore, in this tumour setting, constitutive c-MYC expression circumvents the requirement for
EBV to drive proliferation, but it does place an imperative on EBV to block cellular apoptosis
during oncogenesis. One well-characterised pro-apoptotic pathway activated by c-MYC is the
ARF-MDM2-p53-axis. Accordingly, around 30% of BL biopsies [247] and 70% of BL cell lines
have mutated p53 sequences [248–250]. Furthermore, in BLs where p53 has a wild type sequence,
p14ARF or MDM2 is frequently altered in their expression in order to circumvent p53-dependent cell
death [251,252]. Additionally, deregulation of the downstream BCL-2 family pathway accelerates
MYC-induced lymphomagenesis in the Eµ-Myc mouse model of BL, which carries a c-MYC; IgM heavy
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chain enhancer transgene. Blocking the intrinsic apoptotic pathway through genetic deletion of
pro-apoptotic BCL-2 family genes or constitutive overexpression of BCL-2 pro-survival proteins can all
accelerate lymphoma onset in this mouse model [253–259]. Furthermore, silencing of the pro-apoptotic
BH3-only genes PUMA and BIM has been described in human BL tumours [260,261].
Interestingly, c-MYC itself is frequently mutated in BL, and this is hypothesised to reflect a need to
avoid apoptosis activation whilst retaining or enhancing proliferative capability [262–265]. Indeed, one
c-MYC mutant that commonly occurs in BL has been reported to be incapable of inducing BIM and
consequently cannot trigger cells into apoptosis [266]. Outside of the p53 and BCL-2 pathways, mutations
in other pro-survival signalling pathways may also play a role in BL. Recent genome-wide studies have
identified the transcription factor E2A (TCF-3), ID3, and cyclin D3 as frequently mutated in BL biopsies
and cell lines [262,265,267–269]. Interestingly, these targets all contribute to a third survival axis, which
is ultimately co-ordinated by PI3K—hence several different diversion mechanisms may contribute to
apoptosis escape in BL (reviewed in [270]).
5.2. The Contribution of EBV
In EBV-positive BL, the virus is present as multiple viral episomes in every tumour cell and is
maintained indefinitely, suggesting a selective advantage associated with virus retention. Treating BL
cells with a dominant negative derivative of the viral episome maintenance protein, EBNA1 (dnEBNA1),
enforces loss of viral genomes and induces apoptosis, suggesting that EBV is essential for the continued
survival of these BL cells [271,272]. Incidences of EBV-negative BL do occur, albeit with lower frequency,
and interestingly analyses have revealed EBV-positive and -negative BLs to be genetically distinct;
differing in the number of somatic mutations, frequency of chromosomal copy number changes and the
precise c-MYC translocations [262,273–277]. This suggests that EBV-positive and -negative BLs arise via
slightly different pathogenic routes and furthermore, that the role of EBV in BL needs to be examined
in the context of virus positive lymphomas. Given that subversion of apoptosis is an essential step in
MYC-driven lymphomagenesis [278], it has long been suggested that EBV may provide protection against
intrinsic apoptosis in the established tumour.
5.3. Restricted EBV Latency in BL
5.3.1. Latency I
In 85% of eBLs, the virus expresses only EBNA1, the EBER transcripts and the miR-BARTs,
collectively termed Latency I (Figure 1). EBNA1, EBERs and miR-BARTs are found to be expressed in all
EBV-associated malignancies, but when expressed in the absence of the other latent proteins, this Latency
I pattern is the most restricted form of viral gene expression found in EBV-associated cancers. Thus, the
Latency I gene products constitute the minimum ongoing contribution of EBV to cancer. The nature of
this ongoing viral contribution to BL has been much discussed, but remains somewhat controversial.
In 1994, a report that spontaneous loss of EBV from a sporadic BL cell line called Akata-BL increased
the sensitivity of the cells to apoptosis, impaired their growth and rendered them non-tumorigenic in
a mouse model, provided compelling evidence that the virus remains critical for the survival of BL
cells. Furthermore, it demonstrated for the first time a system in which isogenic cells that contained
or had ‘lost’ the virus could be directly compared [279]. This group later showed that the ‘EBV-loss’
phenotype could be reversed by restoring the virus genome—a key result which directly implicated the
virus as a protective agent in BL [280]. A different group used hydroxyurea to eliminate the viral genome
from two BL cell lines; Mutu-BL and Akata-BL, but found that only Akata-BL-derived EBV-loss cells
showed an increase in apoptosis sensitivity [281]. An alternative strategy was used by the Sugden group,
who found that enforced loss of EBV genomes using dnEBNA1 consistently induces apoptosis in BL
cells [271,272,282–284]. Although this approach convincingly demonstrates the complete dependency
of BL cells on EBV for their ongoing survival, the toxic nature of the phenotype makes it difficult to
isolate EBV-loss clones for comparison with EBV-positive cells, as was previously done. Recently we
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reported a large-scale study investigating the rates of spontaneous EBV loss from BL cell lines and found
that, whilst the phenomenon is rare (loss clones comprised just 3% of those screened), it was consistently
associated with an increase in apoptosis sensitivity. Importantly, and consistent with other laboratories,
we showed that reinfection of EBV-loss BL cells with recombinant EBV and the establishment of a Latency
I infection could reverse the apoptosis-sensitive phenotype [280,285,286].
The mechanism of apoptosis protection by EBV in Latency I BL appears to be cooperative and
to exhibit redundancy. Whilst EBERs are reported to promote survival by upregulating IL10 in some
clonal EBV-loss variants of Akata-BL [287], we and others have found that neither EBNA1 nor EBERs
alone can restore apoptosis protection to EBV-loss BLs [285,286,288]. Interestingly however, the Sample
group, who first showed that EBERs alone could not protect BL cells, did find that BL cells expressing
both EBNA1 and EBERs were tumorigenic in vivo, although to a lesser extent than BL cells infected
with wt EBV [288]. Additionally, whilst we have found that expression of miR-BARTs alone could
not confer any protection to EBV-loss BL cells [285], miR-BARTs, when expressed in combination with
EBNA1, have been shown to reduce dnEBNA1-induced cell death [187]. Furthermore, when EBV-loss
cells were reinfected with a recombinant, Latency I-restricted EBV that lacks many of the miR-BARTs, they
exhibited a moderate, but significant reduction in apoptosis resistance [285]. As mentioned previously
(see Section 2.6), LMP2A can regulate important cell death pathways. Accordingly, ectopic expression
of LMP2A has been shown to protect some BL cell lines from apoptosis [121,289], and can enhance
tumorigenicity in a mouse model [290,291]. However, whilst LMP2 transcripts are detectable in BL
tumour material [292–294], absolute quantitation has shown that the abundance of these transcripts in
Latency I cells is low compared to those found in other forms of latency [33,193]. Additionally, LMP2A
protein expression is a consistent feature of LCLs and Latency II malignancies, however is rarely detected
in BL cells [33,292]. Therefore, it has been extensively demonstrated that optimal cell death inhibition
in Latency I BL can only be conferred by the presence and cooperation of all of the Latency I-associated
EBV genes. Although the precise mechanisms by which each Latency I gene product inhibits cell death
in BL has not been fully elucidated, the collective presence of all Latency I products can block the
induction of both BIM and PUMA following apoptotic challenge [285]. BIM and PUMA translation is
likely inhibited by miR-BARTs as their 3′-UTRs contain multiple predicted binding sites for a variety of
BART miRNAs [165,192,295,296], though miR-BARTs alone are insufficient to appreciably downregulate
BIM and/or PUMA in BL cells [285]. EBERs meanwhile, may contribute to the suppression of BIM and
PUMA induction via activation of AKT/PI3K signalling [297], which has been shown to regulate BIM
and PUMA expression at both transcriptional and post-translational level [298]. PUMA is also subject
to regulation by the TGF-β pathway [299,300], which EBNA1 has been shown to modulate through
downregulation of SMAD2 [82,301]. Caspase 3 expression is also reduced in both EBV-positive and
miR-BART expressing Latency I BL cells compared to levels in dnEBNA1-treated control cells [187].
Therefore, it is possible that there is a third, downstream pro-apoptotic target for Latency I EBV genes.
The importance of BIM and PUMA in BL cell survival has also been demonstrated by the finding that
their expression is often selected against by epigenetic silencing [64,260], though further work is required
to establish whether these changes occur more commonly in EBV-negative versus EBV-positive tumours.
In summary, the Latency I EBV genes (EBNA1, EBERs and miR-BARTs), collectively suppress induction
of pro-apoptotic BIM and PUMA via cooperative targeting of their transcription and translation in order
to overcome a c-MYC-induced sensitivity to apoptosis.
5.3.2. Wp-Restricted Latency
In the remaining ~15% of eBLs, EBV adopts a more extensive pattern of gene expression involving
EBNA-3A, -3B and -3C, a truncated form of EBNA-LP and the BHRF1 protein, in addition to
EBNA1, EBERs and miR-BARTs [19,302,303]. More recently, we have also found that two of the
three BHRF1 miRNAs are also expressed in these tumours [24]. This pattern of gene expression,
termed Wp-restricted Latency (Wp-BL) is imposed by a large deletion in the virus genome and is
associated with marked resistance to cell death [302]. The exact size of the deletion varies between
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tumour samples, but always encompasses the coding region of the EBNA2 gene, placing BHRF1
adjacent to the promoter-encoding Wp repeat region [303]. This promoter, which is silent in Latency I
BL, drives high levels of BHRF1 expression and also transcribes the EBNA proteins [19]. EBNA-3A and
-3C are known to cooperatively downregulate BIM and p16INK4a through epigenetic silencing leading to
reduced sensitivity to cell death [59,64,65,304]. However, it has been shown that short-term expression
of EBNA3s, either individually or in combination, cannot protect BL cells to the same extent as
Wp-restricted latency [19]. Wp-BLs also express a variant of EBNA-LP that is truncated (t-EBNA-LP)
compared to the form expressed in Latency III as a result of the characteristic EBV genomic deletion.
Interestingly, this t-EBNA-LP has also been shown to contribute to cell survival via inhibition of
protein phosphatase 2A (PP2A), a function apparently specific to the truncated form and not shared
by the full length EBNA-LP [305]. BHRF1, by virtue of the fact that it is a viral BCL-2 homologue,
can efficiently inhibit cell death even in the absence of other EBV genes via binding to and inhibition
of cellular pro-apoptotic proteins BIM, PUMA, BID and BAK [19,133]. The propensity of BHRF1
to bind particular pro-death cellular proteins may vary under different conditions of cell stress
(unpublished data from our lab). Therefore, EBV likely exhibits potent cell death inhibition in Wp-BL
through a cooperative mechanism involving the EBNA3, t-EBNA-LP and BHRF1 proteins and possibly
miR-BHRF1s, though the role of the miRNAs may be an indirect effect on regulation of BHRF1
itself [31].
6. Future Perspectives
Cooperation among EBV genes to inhibit cell death is clearly important for both growth
transformation and the pathogenesis of BL; however, relatively little is known about how EBV genes
cooperate outside of these models. There is evidence in the literature to suggest that EBV targets common
pathways in different disease settings. For example, EBV is now known to be an etiologic factor in
around 9% of gastric carcinomas (GC). As in other EBV-associated cancers, the virus is present as a latent
infection in these tumours, although there are conflicting reports as to whether it establishes Latency I
or II infection (the latter involves expression of LMP1 and LMP2 proteins in addition to the Latency I
genes) [306]. Like BL, EBV-positive and -negative cases of GC are genetically distinct. EBV-positive GCs
can be distinguished by marked hypermethylation of genes, including universal silencing of p16INK4A,
and frequent characteristic mutations in PIK3CA, ARID1A and BCOR genes [306,307]. The silencing of
p16INK4A and the 80% incidence of mutations in the PI3K family gene, PIK3CA, suggest that the same
key signalling pathways identified in BL and LCLs are also important in GC pathogenesis. Similarly, in
the setting of NPC, where EBV establishes a Latency II infection, the INK4A locus (encoding p16INK4A
and p14ARF) is commonly mutated or silenced. Therefore, possible cooperation between EBV genes to
regulate key survival signalling pathways, in particular BCL-2 family signalling, PI3K signalling and the
ARF-MDM2-p53-axis, in EBV-associated cancers warrants further investigation.
Whilst it is clear that the known latent genes of EBV make a considerable contribution to the
apoptosis phenotype of EBV-associated cancers, the roles of other EBV-encoded genes in this regard
require further attention. Lytic-cycle-associated transcripts can be readily detected in EBV-positive
cancers [33,193,267,306,308] and though these are thought to originate from the small percentage of cells
within the population that spontaneously undergo lytic replication, more detailed single cell analyses
are required to confirm whether any of these transcripts (and where relevant, the proteins they encode)
are detectable in otherwise latently infected tumour cells. For example, the expression of BHRF1 protein
was initially thought to be restricted to the lytic cycle [131], however it is now known to be expressed
in latently infected Wp-BL and LCLs [19]. Of note in this regard, BHRF1 transcripts have also been
reported in 15–20% of otherwise latent EBV-positive GC biopsies, whilst BARF1 transcripts were detected
in 40–100% of samples (6/13 and 9/9 biopsies, respectively) [309,310]. Furthermore, BALF1 has also
been detected in 80% of NPC biopsies (13/16) [311]. This analysis is further complicated by the findings
that BARF1 can be secreted from EBV infected cells [312] and certain EBV gene products, including
BART miRNAs and LMP proteins, can be released from infected cells in exosomes, and thereby influence
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the survival of neighbouring cells [313] (EBV exosomes reviewed in [314]). Evidence is also emerging
that novel splice variants of LMP2A (and possibly other latent genes) may be expressed during the
lytic cycle or in rarely infected cell types, such as NK or T cells, raising the possibility for additional or
modified apoptosis-regulating functionality by latent genes in these settings [315,316]. New techniques to
genetically modify EBV genomes in situ, such as CRISPR/Cas9 [232,317], will be critical to dissect the
contribution(s) of these lesser characterised EBV genes.
Whilst the evidence that EBV can regulate apoptosis is compelling, future investigations may also
uncover mechanisms through which EBV can modulate additional forms of cell death. For example,
the LMP1 protein has been reported to modulate autophagy by both NF-κB-dependent and -independent
mechanisms [318,319] and autophagy has recently been reported to play an important role in cell survival
during growth transformation of B cells [217]. Furthermore, a number of recent studies have identified
viral modulators of emerging cell death processes, such as necroptosis and pyroptosis in viruses including
cytomegalovirus, vaccinia virus and hepatitis C virus [320–322]. Whilst little is known about EBV in
this regard, these findings further open up the field of viral modulation of cell death. Therefore, whilst
the study of growth transformation and BL have had a profound impact on our understanding of EBV
manipulation of cell survival, future work taking into account the possibility of cooperation among the
full spectrum of EBV genes in regulating both well-characterised and emerging cell death pathways will
be key to the development of new therapeutic approaches.
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